SCHEMBL3077262

SCHEMBL3077262

Cc1nn2ccc(O)cc2c1C=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.34
CYP1A2 P05177 3/20 0.34
CYP2C9 P11712 3/20 0.34
ERN1 O75460 1/20 0.33
LMNA P02545 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
CA12 O43570 1/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
AKR1B1 P15121 1/20 0.32
UGT1A1 P22309 1/20 0.32
MAOB P27338 1/20 0.32
CASP1 P29466 1/20 0.32
KDR P35968 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3077151 0.83 ALDH1A1 (0.40) HPGDCYP1A2CYP2C9LMNASMN1; SMN2
SCHEMBL24882995 0.75 MAPT (0.33) HPGDCYP1A2CYP2C9ERN1LMNA
SCHEMBL3070035 0.75 HPGD (0.46) HPGDCYP1A2CYP2C9LMNASMN1; SMN2
SCHEMBL11153534 0.70 HTR1A (0.31)
SCHEMBL26670496 0.70 PDE4D (0.50) HPGDLMNASMN1; SMN2MAPTKDM4E
SCHEMBL3065072 0.67 HTR2A (0.39) ERN1MEN1KMT2ATRIM24TRIM33
SCHEMBL21407584 0.67 LMNA (0.37) HPGDCYP1A2CYP2C9LMNASMN1; SMN2
SCHEMBL3822190 0.65 MAPK14 (0.47) HPGDCYP1A2CYP2C9LMNAMAPT
SCHEMBL28574881 0.62 SMN1; SMN2 (0.36) HPGDLMNASMN1; SMN2MAPTL3MBTL1
SCHEMBL684215 0.62 PDE5A (0.68) CYP1A2CYP2C9CYP2C19KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176260-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-04-21 EP claimed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 WO claimed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 US disclosed
EP-2176260-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-04-21 EP disclosed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY TP53, PNPO, DPYD HPGD 281/4885CYP1A2 787/4885CYP2C9 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.